blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2609117

EP2609117 - ANTIBODIES AGAINST IL-18R1 AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.07.2016
Database last updated on 14.05.2024
Most recent event   Tooltip19.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 21.11.2018  [2018/47]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[N/P]
Former [2013/27]For all designated states
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Inventor(s)01 / BRANDT, Michael
Faltergatter 29
82393 Iffeldorf / DE
02 / FISCHER, Jens
Baerenmuehlweg 15
82362 Weilheim in Oberbayern / DE
03 / JENEWEIN, Stefan
Vogelsangstrasse 6
67433 Neustadt/Weinstrasse / DE
04 / KALUZA, Klaus
Tankenrain 3
82362 Weilheim / DE
05 / SEEBER, Stefan
Breunetsrieder Weg 22
82377 Penzberg / DE
06 / SAMY, Eileen
20 River Court Apt. 3502
Jersey City New Jersey 07310 / US
 [2013/27]
Representative(s)Burger, Alexander, et al
Roche Diagnostics GmbH
Patentabteilung
Nonnenwald 2
82377 Penzberg / DE
[N/P]
Former [2013/27]Burger, Alexander, et al
Roche Diagnostics GmbH Patent Department (LPP.....6164) P.O.Box 11 52
82372 Penzberg / DE
Application number, filing date11746573.223.08.2011
[2015/38]
WO2011EP64487
Priority number, dateEP2010017403925.08.2010         Original published format: EP 10174039
[2013/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012025536
Date:01.03.2012
Language:EN
[2012/09]
Type: A1 Application with search report 
No.:EP2609117
Date:03.07.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 01.03.2012 takes the place of the publication of the European patent application.
[2013/27]
Type: B1 Patent specification 
No.:EP2609117
Date:16.09.2015
Language:EN
[2015/38]
Search report(s)International search report - published on:EP01.03.2012
ClassificationIPC:C07K16/28, A61K39/395
[2013/27]
CPC:
C07K16/2866 (EP,US); C07K16/24 (KR); A61K39/395 (KR);
A61P11/00 (EP); A61P17/02 (EP); A61P17/06 (EP);
A61P19/00 (EP); A61P19/02 (EP); A61P19/04 (EP);
A61P19/08 (EP); A61P29/00 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P37/02 (EP); A61P37/06 (EP);
C12N15/11 (KR); C07K2317/24 (EP,US); C07K2317/33 (EP,US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/27]
TitleGerman:ANTIKÖRPER GEGEN IL-18R1 UND IHRE VERWENDUNG[2013/27]
English:ANTIBODIES AGAINST IL-18R1 AND USES THEREOF[2013/27]
French:ANTICORPS CONTRE IL-18R1 ET LEURS UTILISATIONS[2013/27]
Entry into regional phase25.03.2013National basic fee paid 
25.03.2013Designation fee(s) paid 
25.03.2013Examination fee paid 
Examination procedure16.01.2013Amendment by applicant (claims and/or description)
25.03.2013Examination requested  [2013/27]
02.01.2014Despatch of a communication from the examining division (Time limit: M06)
08.08.2014Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
30.09.2014Reply to a communication from the examining division
21.10.2014Despatch of a communication from the examining division (Time limit: M04)
12.02.2015Reply to a communication from the examining division
08.04.2015Communication of intention to grant the patent
22.07.2015Fee for grant paid
22.07.2015Fee for publishing/printing paid
22.07.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.01.2014
Opposition(s)17.06.2016No opposition filed within time limit [2016/34]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
30.09.2014Request for further processing filed
30.09.2014Full payment received (date of receipt of payment)
Request granted
15.10.2014Decision despatched
Fees paidRenewal fee
07.08.2013Renewal fee patent year 03
07.08.2014Renewal fee patent year 04
07.08.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.08.2011
AL16.09.2015
AT16.09.2015
BE16.09.2015
BG16.09.2015
CY16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
MC16.09.2015
MK16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SI16.09.2015
SK16.09.2015
SM16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
[2018/47]
Former [2018/38]HU23.08.2011
AT16.09.2015
BE16.09.2015
BG16.09.2015
CY16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
MC16.09.2015
MK16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SI16.09.2015
SK16.09.2015
SM16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2018/31]HU23.08.2011
AT16.09.2015
BE16.09.2015
CY16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
MC16.09.2015
MK16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SI16.09.2015
SK16.09.2015
SM16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2018/28]HU23.08.2011
AT16.09.2015
BE16.09.2015
CY16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
MC16.09.2015
MK16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SI16.09.2015
SK16.09.2015
SM16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2017/23]AT16.09.2015
BE16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
MC16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SI16.09.2015
SK16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2017/03]AT16.09.2015
BE16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SI16.09.2015
SK16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2016/49]AT16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SI16.09.2015
SK16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2016/39]AT16.09.2015
CZ16.09.2015
DK16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SK16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2016/24]AT16.09.2015
CZ16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
NL16.09.2015
PL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SK16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
PT18.01.2016
Former [2016/23]CZ16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
NL16.09.2015
RO16.09.2015
RS16.09.2015
SE16.09.2015
SK16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
Former [2016/22]CZ16.09.2015
EE16.09.2015
FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
NL16.09.2015
RS16.09.2015
SE16.09.2015
NO16.12.2015
GR17.12.2015
IS16.01.2016
Former [2016/14]FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
NL16.09.2015
RS16.09.2015
SE16.09.2015
NO16.12.2015
GR17.12.2015
Former [2016/11]FI16.09.2015
HR16.09.2015
LT16.09.2015
LV16.09.2015
RS16.09.2015
SE16.09.2015
NO16.12.2015
GR17.12.2015
Former [2016/09]FI16.09.2015
LT16.09.2015
LV16.09.2015
NO16.12.2015
GR17.12.2015
Former [2016/08]LT16.09.2015
NO16.12.2015
Former [2016/07]LT16.09.2015
Cited inInternational search[IY]EP1808446  (SEKIYAMA ATSUO [JP]) [I] 2,3,21,25 * paragraph [0219] - paragraph [0221]; table 1 * [Y] 14,16,17;
 [IY]WO2007117577  (REGENERON PHARMA [US], et al) [I] 2,3,21,25 * example 1 * * tables 1-2,4 * [Y] 6-8,14,16-18;
 [XYI]  - NISHIDA Y ET AL, "CLONING AND EXPRESSION OF A SINGLE-CHAIN FV FRAGMENT SPECIFIC FOR THE HUMAN INTERLEUKIN 18 RECEPTOR", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, (19981201), vol. 17, no. 6, ISSN 0272-457X, pages 577 - 580, XP000973543 [X] 1,9-11 * figure 2B * * figure 1 * [Y] 6-8,14,16-18 [I] 2,3,21,25
 [XYI]  - KUNIKATA T ET AL, "CONSTITUTIVE AND INDUCED IL-18 RECEPTOR EXPRESSION BY VARIOUS PERIPHERL BLOOD CELL SUBSETS AS DETERMINED BY ANTI-HIL-18R MONOCLONAL ANTIBODY", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, (19981101), vol. 189, doi:DOI:10.1006/CIMM.1998.1376, ISSN 0008-8749, pages 135 - 143, XP000973461 [X] 1 * page 136, paragraph right * [Y] 6-8,14,16-18 [I] 2,3,21,25

DOI:   http://dx.doi.org/10.1006/cimm.1998.1376
 [XYI]  - ZHANG B ET AL, "Expression of IL-18 and its receptor in human leukemia cells", LEUKEMIA RESEARCH, NEW YORK,NY, US, (20030101), vol. 27, no. 9, doi:DOI:10.1016/S0145-2126(03)00005-5, ISSN 0145-2126, pages 813 - 822, XP002992961 [X] 1,12,13,15,19,20,22-24 * paragraph [02.2] * * figure 2 * * table 3 * [Y] 6-8,14,16-18 [I] 2,3,21,25

DOI:   http://dx.doi.org/10.1016/S0145-2126(03)00005-5
 [XYI]  - "Human IL-18 R alpha/IL-1 R5 MAb (Clone 70625)", INTERNET CITATION, (20050218), URL: http://www.rndsystems.com/pdf/mab840.pdf, (20071005), XP002454080 [X] 1 * the whole document * [Y] 6-8,14,16-18 [I] 2,3,21,25
 [XYI]  - VERMOT-DESROCHES C ET AL, "Monoclonal antibodies specific for the IL-18 receptor", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 236, no. 1-2, ISSN 0008-8749, (20050701), pages 101 - 104, (20051212), XP027189887 [X] 1 * figure 2 * [Y] 6-8,14,16-18 [I] 2,3,21,25
 [XYI]  - Serotec Ltd., "Serotec Immunological Excellence - Supplement - Issue 1, 2003", (2003), Internet, URL: http://www.abdserotec.com/uploads/supplement-2003-02.pdf, (20110504), XP002635224 [X] 1 * page 7 * [Y] 6-8,14,16-18 [I] 2,3,21,25
 [XYI]  - HOSOTANI YUKA ET AL, "Interleukin-18 prevents apoptosis via PI3K/Akt pathway in normal human keratinocytes.", THE JOURNAL OF DERMATOLOGY AUG 2008 LNKD- PUBMED:18789072, (200808), vol. 35, no. 8, ISSN 0385-2407, pages 514 - 524, XP002635225 [X] 1 * page 515, column right * [Y] 6-8,14,16-18 [I] 2,3,21,25

DOI:   http://dx.doi.org/10.1111/j.1346-8138.2008.00513.X
 [A]  - HEZAREH M ET AL, "Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.", JOURNAL OF VIROLOGY DEC 2001 LNKD- PUBMED:11711607, (200112), vol. 75, no. 24, ISSN 0022-538X, pages 12161 - 12168, XP002635226 [A] 6-8 * figures 2-3 *

DOI:   http://dx.doi.org/10.1128/JVI.75.24.12161-12168.2001
 [A]  - KANG M J E TAL, "IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20070201), vol. 178, no. 3, ISSN 0022-1767, pages 1948 - 1959, XP008130670 [A] 14,16,17 * the whole document *
Examination   - "Competitive inhibition", INTERNET CITATION, (20110913), pages 1 - 5, URL: http://en.wikipedia.org/wiki/Competitive_inhibition, (20111003), XP002660444
by applicantUS4676980
 US4737456
 US4816567
 EP0404097
 WO9301161
 WO9308829
 WO9316185
 WO9429351
 US5500362
 US5571894
 US5587458
 US5624821
 US5648260
 US5648237
 WO9730087
 US5731168
 US5789199
 US5821337
 US5840523
 WO9858964
 US5869046
 WO9922764
 WO9937772
 US5959177
 WO9951642
 US6040498
 WO0061739
 EP1047781
 US6171586
 US6194551
 WO0129246
 US6248516
 US6267958
 WO0185201
 WO0208272
 WO0231140
 US6417429
 US6420548
 US2002164328
 WO03008452
 WO03012061
 WO03011878
 US2003115614
 WO03057821
 US6600022
 US6602684
 US2003157108
 WO03080104
 WO03085119
 WO03084570
 WO03085107
 US2004093621
 US6737056
 US2004110704
 US2004110282
 US2004109865
 US2004132140
 WO2004056312
 US2005014934
 WO2005012352
 WO2005035586
 WO2005035778
 US2005123546
 WO2005053742
 WO2005097998
 WO2005100402
 US2005260186
 WO2006009114
 US2006025576
 WO2006029879
 WO2006044908
 US2006104968
 US7125978
 US7141393
 US7169581
 WO2007096398
 WO2007117577
 US7332581
 WO2008027236
 US2008063644
 US2008069820
 US7371826
 WO2008077546
 WO2009015284
 US7521541
 WO2009074634
 WO2009089004
 US7615220
 WO2010011697
 US7704945
    - NAKANISHI, K. ET AL., ANN. REV. IMMUNOL., (2001), vol. 19, pages 423 - 474
    - GRUMELLI, S. ET AL., PLOS MEDICINE, (2004), vol. 1, pages 75 - 83
    - MA ET AL., J. CLIN. INVEST., (2005), vol. 115, pages 3460 - 3472
    - WANG, Z. ET AL., J. EXP. MED., (2000), vol. 192, pages 1587 - 1599
    - SUTHERLAND, CHEMIACK, N. ENGL. J. MED., (2004), vol. 350, pages 2689 - 2697
    - HOSHINO, T. ET AL., AM. J. RESPIR. CRIT. CARE MED., (2007), vol. 176, pages 49 - 62
    - KANG, M.J. ET AL., J. IMMUNOL., (2007), vol. 178, pages 1948 - 1959
    - KANG, M.J., J. CLIN. INVEST., (2008), vol. 118, pages 2771 - 2784
    - PARNET, P. ET AL., J. BIOL. CHEM., (1996), vol. 271, pages 3967 - 3970
    - TORIGOE, K. ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 25737 - 25742
    - ANGAL, S. ET AL., MOL. IMMUNOL., (1993), vol. 30, pages 105 - 108
    - RIECHMANN, L. ET AL., NATURE, (1988), vol. 332, pages 323 - 327
    - NEUBERGER, M.S. ET AL., NATURE, (1985), vol. 314, pages 268 - 270
    - QUEEN, C. ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 10029 - 10033
    - CHOTHIA, C., LESK, A.M., J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - ALMAGRO, J.C., FRANSSON, J., FRONT. BIOSCI., (2008), vol. 13, pages 1619 - 1633
    - FLATMAN, S. ET AL., J. CHROMATOGR. B, (2007), vol. 848, pages 79 - 87
    - KINDT ET AL., Kuby Immunology, sixth ed.,, W.H. FREEMAN AND CO., (2007), page 91
    - PORTOLANO, S. ET AL., J. IMMUNOL., (1993), vol. 150, pages 880 - 887
    - CLARKSON, T. ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - CHEN, Y. ET AL., J. MOL. BIOL., (1999), vol. 293, pages 865 - 881
    - HUDSON, P.J. ET AL., NAT. MED., (2003), vol. 9, pages 129 - 134
    - PLUECKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - MILSTEIN, C., CUELLO, A.C., NATURE, (1983), vol. 305, pages 537 - 540
    - TRAUNECKER, A. ET AL., EMBO J., (1991), vol. 10, pages 3655 - 3659
    - BRENNAN, M. ET AL., SCIENCE, (1985), vol. 229, pages 81 - 83
    - KOSTELNY, S.A. ET AL., J. IMMUNOL., (1992), vol. 148, pages 1547 - 1553
    - GRUBER, M. ET AL., J. IMMUNOL., (1994), vol. 152, pages 5368 - 5374
    - TUTT, A. ET AL., J. IMMUNOL., (1991), vol. 147, pages 60 - 69
    - WRIGHT, A. ET AL., TIBTECH, (1997), vol. 15, pages 26 - 32
    - OKAZAKI, A. ET AL., J. MOL. BIOL., (2004), vol. 336, pages 1239 - 1249
    - YAMANE-OHNUKI, N. ET AL., BIOTECH. BIOENG., (2004), vol. 87, pages 614 - 622
    - RIPKA, J. ET AL., ARCH. BIOCHEM. BIOPHYS., (1986), vol. 249, pages 533 - 545
    - KANDA, Y. ET AL., BIOTECHNOL. BIOENG., (2006), vol. 94, pages 680 - 688
    - RAVETCH, J.V., KINET, J.P, ANNU. REV. IMMUNOL., (1991), vol. 9, pages 457 - 492
    - HELLSTROM, I. ET AL., PROC. NATL. ACAD. SCI. USA, (1986), vol. 83, pages 7059 - 7063
    - HELLSTROM, I. ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, pages 1499 - 1502
    - BRUEGGEMANN, M. ET AL., J. EXP. MED., (1987), vol. 166, pages 1351 - 1361
    - CLYNES, R. ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 652 - 656
    - GAZZANO-SANTORO, H. ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, pages 163 - 171
    - CRAGG, M.S. ET AL., BLOOD, (2003), vol. 101, pages 1045 - 1052
    - CRAGG, M.S., M.J. GLENNIE, BLOOD, (2004), vol. 103, pages 2738 - 2743
    - PETKOVA, S.B. ET AL., INTL. IMMUNOL., (2006), vol. 18, pages 1759 - 1769
    - SHIELDS, R.L. ET AL., J. BIOL. CHEM., (2001), vol. 276, pages 6591 - 6604
    - IDUSOGIE, E.E. ET AL., J. IMMUNOL., (2000), vol. 164, pages 4178 - 4184
    - GUYER, R.L. ET AL., J. IMMUNOL., (1976), vol. 117, pages 587 - 593
    - KIM, J.K. ET AL., J. IMMUNOL., (1994), vol. 24, pages 2429 - 2434
    - DUNCAN, A.R., WINTER, G., NATURE, (1988), vol. 332, pages 738 - 740
    - KAM, N.W. ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 11600 - 11605
    - CHARLTON, K.A., Methods in Molecular Biology, HUMANA PRESS, (2003), vol. 248, pages 245 - 254
    - GERNGROSS, T.U., NAT. BIOTECH., (2004), vol. 22, pages 1409 - 1414
    - LI, H. ET AL., NAT. BIOTECH., (2006), vol. 24, pages 210 - 215
    - GRAHAM, F.L. ET AL., J. GEN VIROL., (1977), vol. 36, pages 59 - 74
    - MATHER, J.P, BIOL. REPROD., (1980), vol. 23, pages 243 - 252
    - MATHER ET AL., ANNALS N.Y. ACAD. SCI., (1982), vol. 383, pages 44 - 68
    - URLAUB, G. ET AL., PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, pages 4216 - 4220
    - YAZAKI, P.J. ET AL., METHODS IN MOLECULAR BIOLOGY, (2003), vol. 248, pages 255 - 268
    - KEARNS J.D., HOFFMANN, A., J. BIOL. CHEM., (2009), vol. 284, pages 5439 - 5443
    - TOMINAGA, K. ET AL., INT. IMMUNOL., (2000), vol. 12, pages 151 - 160
    - ZHU, X. ET AL., J. IMMUNOL., (2009), vol. 182, pages 3270 - 3277
    - FREEMAN, C.M. ET AL., J. IMMUNOL., (2010), vol. 184, pages 6504 - 6513
    - SHIRAI, T. ET AL., ALLERGOL. INT., (2010), vol. 59, pages 75 - 82
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.